Valneva (VLA) Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VLA Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.17 |
| 52 Week High | €5.42 |
| 52 Week Low | €2.25 |
| Beta | 1.2 |
| 1 Month Change | -2.07% |
| 3 Month Change | 6.49% |
| 1 Year Change | 12.65% |
| 3 Year Change | -31.02% |
| 5 Year Change | -67.28% |
| Change since IPO | -61.97% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Oct 01
Is Valneva (EPA:VLA) Using Too Much Debt?
Sep 10Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Jul 24
Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Feb 20Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Feb 06Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Nov 22€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Nov 10Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Sep 19Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 17Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 10Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15Shareholder Returns
| VLA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 6.8% | 3.9% | 1.9% |
| 1Y | 12.6% | 301.3% | 1.3% |
Return vs Industry: VLA underperformed the French Biotechs industry which returned 299.3% over the past year.
Return vs Market: VLA exceeded the French Market which returned 1.2% over the past year.
Price Volatility
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in FR Market | 11.1% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: VLA's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: VLA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VLA fundamental statistics | |
|---|---|
| Market cap | €724.20m |
| Earnings (TTM) | -€102.16m |
| Revenue (TTM) | €179.91m |
Is VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLA income statement (TTM) | |
|---|---|
| Revenue | €179.91m |
| Cost of Revenue | €183.61m |
| Gross Profit | -€3.69m |
| Other Expenses | €98.47m |
| Earnings | -€102.16m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 01, 2026
| Earnings per share (EPS) | -0.59 |
| Gross Margin | -2.05% |
| Net Profit Margin | -56.78% |
| Debt/Equity Ratio | 111.5% |
How did VLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 03:57 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Valneva SE is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |